Subject
Neuro-Oncology is a monthly peer-reviewed medical journal covering cancer of the nervous system. It was established in 1999 and is published by Oxford University Press on behalf of the Society for Neuro-Oncology. The editor-in-chief is Kenneth Aldape. According to the Journal Citation Reports, the journal has a 2019 impact factor of 10.091. Source: Wikipedia (en)
Editions published in Neuro-Oncology 200
Too many entities requested (12099). Only 200 are displayed.
-
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma
-
How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies
-
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas
-
Tumor treating fields: a novel treatment modality and its use in brain tumors
-
Diabetes, use of antidiabetic drugs, and the risk of glioma
-
For glioma, a sweet side to diabetes
-
Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation
-
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
-
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
-
Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells
-
Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis
-
American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.
-
Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma
-
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
-
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma
-
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients
-
Polymeric drug delivery for the treatment of glioblastoma
-
Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review
-
TNF-α enhancement of CD62E mediates adhesion of non-small cell lung cancer cells to brain endothelium via CD15 in lung-brain metastasis
-
High-definition fiber tractography for the evaluation of perilesional white matter tracts in high-grade glioma surgery
-
Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs
-
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
-
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide
-
Telomere maintenance and the etiology of adult glioma
-
Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis
-
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas
-
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
-
Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas.
-
Transcriptional diversity of long-term glioblastoma survivors.
-
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
-
JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma
-
Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations
Subject - wd:Q15724471